Introduction to MS Clinical Relapse Biomarkers

Multiple Sclerosis remains a complex neuroimmunological puzzle, particularly when clinicians must differentiate between a true clinical relapse and a transient pseudoexacerbation. A true relapse involves new inflammatory demyelination within the central nervous system, whereas pseudoexacerbations are temporary symptom flares triggered by external factors like heat, stress, or infection. Identifying MS clinical relapse biomarkers is therefore essential to prevent unnecessary treatments and ensure accurate management. Historically, neurologists have relied heavily on subjective patient-reported symptoms and MRI scans to confirm new activity. However, MRI access can be significantly delayed in many clinical settings, and results do not always align perfectly with the patient's clinical state. Recent advances in serum proteomics have introduced multi-analyte assays that provide a molecular snapshot of the disease in real-time. By measuring specific proteins associated with axonal damage and inflammation, these tests complement traditional diagnostic tools. This evolution toward precision medicine helps bridge the gap between clinical observation and radiological evidence. As the global burden of MS grows, integrating these biomarkers into routine practice offers a pathway toward personalized care. Understanding the utility of these assays is consequently paramount for modern neurological practice.

The Multi-Analyte Advantage in Neurological Care

The Octave Multiple Sclerosis Disease Activity (MSDA) Test represents a significant leap forward in the field of MS clinical relapse biomarkers. This commercially available assay measures 18 distinct proteins in the blood, synthesizing this complex data into a single, actionable Disease Activity Score (DAS). Specifically, key markers included in the panel are neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and myelin oligodendrocyte glycoprotein (MOG). Each protein reflects a different aspect of pathology; for instance, NfL indicates neuroaxonal injury, while GFAP reflects astrocytic activation. By combining these multiple signals, the assay provides a more comprehensive view than any single marker could offer alone. Furthermore, studies show that this multi-analyte approach significantly improves the sensitivity of detecting acute inflammatory activity. In clinical settings, it allows for the objective quantification of disease status, moving beyond binary classifications. Additionally, machine learning algorithms help adjust these protein concentrations based on patient-specific factors such as age and body mass index. This level of personalization is crucial because biomarker levels can vary naturally. For clinicians, having access to proteomic data simplifies the decision-making process, especially when MRI results are inconclusive or unavailable.

Bridging the Gap Between Proteomics and MRI Findings

Recent clinical evaluations have specifically examined how these proteomic results align with magnetic resonance imaging findings. The research focused on participants with relapsing-remitting MS who underwent both MSDA testing and MRI before receiving any glucocorticosteroids. Notably, a key finding was the strong correlation between a DAS score of 6.0 or higher and the presence of gadolinium-enhancing lesions on MRI. This specific threshold proved to be both highly sensitive and specific for predicting active inflammatory relapses. Moreover, symptomatic individuals showed significantly elevated concentrations of NfL and myelin oligodendrocyte glycoprotein compared to those undergoing routine surveillance. This suggests that the proteomic signature of a true relapse is distinct and measurable. Interestingly, the assay often preceded the MRI in symptomatic patients, highlighting its potential role as a rapid triage tool. While MRI remains the definitive method for visualizing structural damage, the multi-analyte assay provides physiological insights that may appear before radiological changes become apparent. Consequently, this allows neurologists to confirm their clinical suspicions with greater confidence. Distinguishing between inflammation-driven relapses and pseudoexacerbations represents a major milestone in reducing the risk of treating pseudo-flares with aggressive immune-modulating therapies.

Clinical Implementation and Disease Monitoring Strategies

The utility of MS clinical relapse biomarkers extends to routine disease surveillance for patients regardless of their current therapy status. Consistent monitoring helps clinicians assess if a disease-modifying therapy (DMT) is effectively suppressing subclinical activity. If a patient shows rising levels of NfL or GFAP despite being on a high-efficacy DMT, it may indicate "silent" disease progression. This proactive approach allows for earlier intervention, potentially switching treatments before significant disability accumulates. Furthermore, study data indicated that the DAS was effective regardless of DMT exposure, suggesting robustness across various treatment scenarios. Additionally, the role of GFAP in reflecting progression independent of relapse activity (PIRA) is gaining recognition. While relapses are the most visible sign of MS, the underlying neurodegeneration often leads to long-term disability. Multi-analyte assays help capture this smoldering inflammation that MRIs might occasionally overlook. Using these tests during routine follow-ups provides a longitudinal view of the patient's health, making it easier to spot deviations from a stable baseline. This continuous monitoring paradigm is especially useful for clinicians managing complex cases where the clinical exam and the patient's reports do not align. Ultimately, this leads to a more nuanced and responsive treatment strategy.

Impact of Specific MS Clinical Relapse Biomarkers

Understanding the individual roles of proteins like neurofilament light and glial fibrillary acidic protein is essential for interpreting assay results. Neurofilament light is released during axonal damage, making it a highly sensitive marker for acute inflammatory events. Its levels typically rise during a relapse and return to baseline as inflammation resolves. Conversely, glial fibrillary acidic protein is linked to astrocyte activation and chronic neurodegeneration. Elevated levels of this protein often correlate with long-term disability progression rather than acute focal flares. Myelin oligodendrocyte glycoprotein also offers critical insights into the status of the myelin sheath during a demyelinating event. When assessed together, these proteins provide a multidimensional view of neurological health that MRI alone cannot provide. For instance, high NfL with stable GFAP might suggest a new focal lesion, while rising GFAP might indicate a transition to a progressive disease phase. This level of detail allows neurologists to move away from generic treatments toward highly individualized care plans. Consequently, the clinical utility of these specific proteins is a cornerstone of modern neuroimmunology and precision medicine in multiple sclerosis management.

Frequently Asked Questions

What is the primary difference between an MS relapse and a pseudoexacerbation?

A true MS clinical relapse is caused by new inflammatory damage and demyelination in the central nervous system, typically lasting more than 24 hours. In contrast, a pseudoexacerbation is a temporary worsening of existing symptoms often triggered by external factors like heat, stress, or infection. While relapses may require corticosteroid treatment, pseudoexacerbations usually resolve once the underlying trigger is addressed without needing aggressive immune-modulating interventions.

How does the Disease Activity Score (DAS) correlate with MRI findings?

The Disease Activity Score (DAS) from the multi-analyte assay has shown a strong correlation with gadolinium-enhancing lesions, which are the radiological hallmark of active inflammation. Research indicates that a DAS of 6.0 or higher is highly sensitive and specific for predicting these active lesions on an MRI. This allows clinicians to use the blood test as a reliable indicator of whether a patient is experiencing a true inflammatory relapse.

Why are NfL and GFAP considered essential MS clinical relapse biomarkers?

Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) provide complementary insights into MS pathology. NfL is a marker of acute axonal injury, rising significantly during inflammatory relapses. GFAP reflects astrocytic activation and is often associated with progression independent of relapse activity (PIRA). By monitoring both, clinicians can distinguish between acute inflammation and chronic neurodegeneration, allowing for a more comprehensive assessment of the patient's disease state and the effectiveness of their therapy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Okuda DT et al. Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation. Neurol Ther. 2026 Jun 27. doi: 10.1007/s40120-026-00984-2. PMID: 42364069.

Chitnis T et al. Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis. Nature Communications. 2024;15:1234.

Sanchez et al. Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2025;11(2).